Overview

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that Besivance is equal to Vigamox in safety and tolerance when used prophylactically in subjects undergoing routine cataract surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Ophthalmology Consultants, Ltd.
Collaborators:
Bausch & Lomb Incorporated
Ophthalmology Associates, St Louis
Treatments:
7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Anti-Bacterial Agents
Antibiotics, Antitubercular
Besifloxacin
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ophthalmic Solutions